Prostate Cancer Metastatic
Conditions
Keywords
Metastatic Castration-Resistant Prostate Cancer, circulating tumor cells, Prognosis, Liquid biopsy
Brief summary
As prostate cancer progresses into castration-resistant stage from initial hormone-sensitive status, the biological behavior of tumor cells that dissociated from primary lesions changed. Considered a liquid biopsy, these circulating tumor cells (CTCs) can show how a patient's cancer responded to treatments. The purpose of this study is to determine whether sequentially analyzing the expression of molecular markers in high volume circulating tumor cells in metastatic castration-resistant prostate cancer patients can predict the therapeutic effects and outcomes of these patients.
Interventions
OTHERBlood drawing
Blood drawing
Sponsors
Fudan University
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Male patients 2. 18 yrs and older, and 80 yrs and younger 3. Histologically or cytologically proven prostate adenocarcinoma; 4. Imaging examinations including Emission Computed Tomography (ECT), Positron Emission Tomography (PET) and so on revealed a high-volume disease of patients(A high-volume of disease was defined by the presence of visceral metastases or four or more bone lesions with at least one beyond the vertebral bodies and pelvis) 5. Have been received hormonal therapy and progressed into castration-resistant stage 6. Not yet receiving chemotherapy 7. Patients are willing to participate and can be followed up regularly
Exclusion criteria
1. Received the treatment of abiraterone acetate previously 2. Patients received chemotherapy previously 3. Combined with other malignant tumor history (in addition to the skin basal cell carcinoma or other tumors that have been cured more than five years).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| overall survival | 2 years | Overall survival was defined as the period of time from inclusion to death from any cause, or to the last follow up date. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| time to prostate specific antigen (PSA) progression | 2 years | time from inclusion to prostate specific antigen (PSA) progression |
| time to radiographic progression | 2 years | time from inclusion to radiographic progression |
| complete serologic response rate at 3 month and 6 month | 1 year | prostate specific antigen response rate at 3 month and 6 month |
Countries
China
Contacts
Primary ContactDai Bo, MD
Outcome results
None listed